Psychiatric genetics, which is growing in size and influence within psychiatry, employs four major research paradigms: 1) basic genetic epidemiology, 2) advanced genetic epidemiology, 3) gene finding methods, and 4) molecular genetics. Paradigms 1 and 2 ...

January 2005

Schizophrenia and Migration: A Meta-Analysis and Review

Elizabeth Cantor-Graae,Ph.D., and
Jean-Paul Selten,Ph.D., M.D.

Pages:12–24
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.12

Preview Abstract

OBJECTIVE: The authors synthesize findings of previous studies implicating migration as a risk factor for the development of schizophrenia and provide a quantitative index of the associated effect size. METHOD: MEDLINE was searched for population-based ...

Images in Neuroscience

January 2005

The Hippocampus

Carol A. Tamminga,M.D., Editor,Dallas, Texas

Page:25
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.25

Introspections

January 2005

The Confession

Ronald Ruskin,M.D.

Pages:26–27
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.26

Clinical Case Conference

January 2005

Persistent Choreoathetosis in a Fatal Olanzapine Overdose: Drug Kinetics, Neuroimaging, and Neuropathology

Pages:28–33
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.28

Images in Psychiatry

January 2005

Frederic William Henry Myers, 1843–1901

Emily W. Kelly,Ph.D., and
Carlos S. Alvarado,Ph.D.

Page:34
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.34

Article

January 2005

Localization of Bipolar Susceptibility Locus by Molecular Genetic Analysis of the Chromosome 12q23-q24 Region in Two Pedigrees With Bipolar Disorder and Darier’s Disease

Elaine Green,Ph.D.,
Gareth Elvidge,Ph.D.,
Nick Jacobsen,Ph.D.,
Beate Glaser,Ph.D.,
Ian Jones,Ph.D., M.R.C.Psych.,
Michael C. O’Donovan,F.R.C.Psych., Ph.D.,
George Kirov,Ph.D., M.R.C.Psych.,
Michael J. Owen,F.R.C.Psych., Ph.D., F.Med.Sci., and
Nick Craddock,Ph.D., M.R.C.Psych.

Pages:35–42
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.35

Preview Abstract

OBJECTIVE: The authors previously reported two families (pedigrees 324 and 5501) in which Darier’s disease—a rare, autosomal dominant skin disease—and bipolar disorder cosegregate. In each of these families there is complete cosegregation of mood disorder ...

January 2005

Diminished Suppression of the P50 Auditory Evoked Potential in Bipolar Disorder Subjects With a History of Psychosis

Ann Olincy,M.D., and
Laura Martin,M.D.

Pages:43–49
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.43

Preview Abstract

OBJECTIVE: People with schizophrenia, schizoaffective disorder, and bipolar illness share clinical symptoms, biological findings, and genetic susceptibility. Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of ...

January 2005

Sleep-Related Functioning in Euthymic Patients With Bipolar Disorder, Patients With Insomnia, and Subjects Without Sleep Problems

Pages:50–57
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.50

Preview Abstract

OBJECTIVE: The authors investigated sleep-related functioning in euthymic patients with bipolar disorder. METHOD: Euthymic patients with bipolar disorder (N=20), patients with insomnia (N=20), and subjects with good sleep (N=20) were compared on data from ...

January 2005

Randomized, Placebo-Controlled Trial of Mixed Amphetamine Salts for Symptoms of Comorbid ADHD in Pediatric Bipolar Disorder After Mood Stabilization With Divalproex Sodium

Pages:58–64
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.58

Preview Abstract

OBJECTIVE: The purpose of this study was to determine whether adjunctive use of a psychostimulant (mixed amphetamine salts) was safe and efficacious for treatment of symptoms of attention deficit hyperactivity disorder (ADHD) in pediatric outpatients with ...

January 2005

An In Vivo MRI Study of Prefrontal Cortical Complexity in First-Episode Psychosis

Pages:65–70
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.65

Preview Abstract

OBJECTIVE: The purpose of this study was to investigate abnormalities in the surface complexity of the prefrontal cortex and in the hemispheric asymmetry of cortical complexity in first-episode patients with schizophrenia. METHOD: An estimate of the ...

January 2005

Memory Impairments Identified in People at Ultra-High Risk for Psychosis Who Later Develop First-Episode Psychosis

Warrick J. Brewer,Ph.D.,
Shona M. Francey,Ph.D.,
Stephen J. Wood,Ph.D.,
Henry J. Jackson,Ph.D.,
Christos Pantelis,F.R.A.N.Z.C.P.,
Lisa J. Phillips,M.Psych.(Clin.),
Alison R. Yung,F.R.A.N.Z.C.P.,
Vicki A. Anderson,Ph.D., and
Patrick D. McGorry,F.R.A.N.Z.C.P.

Pages:71–78
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.71

Preview Abstract

OBJECTIVE: While cognitive deficits are frequently reported in psychotic disorders, it is unclear whether these impairments predate the onset of illness and to what extent they are predictive of later transition to psychosis. METHOD: The authors studied ...

January 2005

Pregnancy, Delivery, and Neonatal Complications in a Population Cohort of Women With Schizophrenia and Major Affective Disorders

Assen V. Jablensky,M.D.,
Vera Morgan,M.Soc.Sc.,
Stephen R. Zubrick,Ph.D.,
Carol Bower,M.B.B.S., Ph.D., and
Li-Anne Yellachich,Ph.D.

Pages:79–91
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.79

Preview Abstract

OBJECTIVE: This study ascertained the incidence of complications during pregnancy, labor, and delivery and the neonatal characteristics of infants born to women with schizophrenia, bipolar disorder, or major depression in a population-based cohort. METHOD:...

January 2005

Facial Expressiveness in Patients With Schizophrenia Compared to Depressed Patients and Nonpatient Comparison Subjects

Pages:92–101
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.92

Preview Abstract

OBJECTIVE: Blunted affect is a major symptom in schizophrenia, and affective deficits clinically encompass deficits in expressiveness. Emotion research and ethological studies have shown that patients with schizophrenia are impaired in various modalities ...

January 2005

Personality Dimensions in First-Episode Psychoses

Pages:102–109
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.102

Preview Abstract

OBJECTIVE: The authors compared the patterns and specificity of premorbid personality dimensions in first-episode schizophrenia patients with those in patients with first-episode nonschizophrenia psychoses and healthy comparison subjects. METHOD: A series ...

January 2005

Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study

Pages:110–117
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.110

Preview Abstract

OBJECTIVE: It is important to understand the stability of cognitive performance in schizophrenia in order to understand 1) the potential improvements in performance associated with the beneficial effects of cognitive-enhancing medications and 2) the ...

January 2005

Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis

Pages:118–123
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.118

Preview Abstract

OBJECTIVE: Weight gain is a commonly observed adverse effect of atypical antipsychotic medications, but associated changes in energy balance and body composition are not well defined. The authors report here the effect of olanzapine on body weight, body ...

January 2005

Olanzapine Treatment of Residual Positive and Negative Symptoms

Pages:124–129
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.124

Preview Abstract

OBJECTIVE: Olanzapine has been hypothesized to have superior efficacy in patients with treatment-resistant schizophrenia. The authors examined the comparative efficacy and safety of olanzapine and haloperidol in outpatients with partially responsive ...

January 2005

Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

Pages:130–136
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.130

Preview Abstract

OBJECTIVE: The authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia. METHOD: In a randomized, double-blind, placebo-controlled 12-week trial, 40 patients unresponsive or ...

January 2005

Does Sustained-Release Lithium Reduce Impulsive Gambling and Affective Instability Versus Placebo in Pathological Gamblers With Bipolar Spectrum Disorders?

Pages:137–145
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.137

Preview Abstract

OBJECTIVE: Selective serotonin reuptake inhibitors may be effective for some patients with pathological gambling, but those with comorbid conditions, such as bipolar spectrum disorders, may relapse during treatment. To the authors’ knowledge, this is the ...

January 2005

Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial

Pages:146–150
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.146

Preview Abstract

OBJECTIVE: Anxiety disorders are highly prevalent in elderly persons. However, to date, the efficacy of selective serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety disorders in this age group has not been established. METHOD: Thirty-four ...

January 2005

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

Pages:151–161
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.151

Preview Abstract

OBJECTIVE: The purpose of the study was to test the relative and combined efficacy of clomipramine and exposure and ritual prevention in the treatment of obsessive-compulsive disorder (OCD) in adults. Serotonin reuptake inhibitors (SRIs) and cognitive ...

January 2005

Osteoporosis in Patients With Schizophrenia

Pages:162–167
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.162

Preview Abstract

OBJECTIVE: Osteoporosis is regularly mentioned as a possible consequence of treatment with prolactin-increasing antipsychotic medications, but little is known about the prevalence and the degree of loss of bone mineral density in patients suffering from ...

January 2005

Bone Mineral Density, Markers of Bone Turnover, and Cytokines in Young Women With Borderline Personality Disorder With and Without Comorbid Major Depressive Disorder

Pages:168–174
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.168

Preview Abstract

OBJECTIVE: The pathogenesis of bone loss in major depressive disorder is a matter of debate. Studies of bone loss in nonpsychiatric medical disorders have found an association between the activation of osteoclastic cells and an imbalance of pro- and ...

Brief Report

January 2005

Increase in Interleukin-1β in Late-Life Depression

Alan J. Thomas,Ph.D., M.R.C.Psych.,
Sue Davis,Ph.D.,
Christopher Morris,Ph.D.,
Elizabeth Jackson,M.R.C.Psych.,
Richard Harrison,M.R.C.Psych., and
John T. O’Brien,D.M., M.R.C.Psych.

Pages:175–177
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.175

Preview Abstract

OBJECTIVE: Depression has been associated with increases in circulating cytokines in younger adults, and there is evidence for prefrontal inflammation in late-life depression. The authors tested the hypothesis that levels of cytokine interleukin-1β (IL-1β)...

January 2005

Is Depression in Old Age Fatal Only When People Feel Lonely?

Max L. Stek,M.D., Ph.D.,
David J. Vinkers,M.D.,
Jacobijn Gussekloo,M.D., Ph.D.,
Aartjan T.F. Beekman,M.D., Ph.D.,
Roos C. van der Mast,M.D., Ph.D., and
Rudi G.J. Westendorp,M.D., Ph.D.

Pages:178–180
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.178

Preview Abstract

OBJECTIVE: The impact of depression and perceived loneliness in the oldest old is largely unknown. The authors studied the relationship between the presence of depressive symptoms and all-cause mortality in old age, especially the potential distorting ...

January 2005

A Pilot Study of Interpersonal Psychotherapy for Posttraumatic Stress Disorder

Kathryn L. Bleiberg,Ph.D., and
John C. Markowitz,M.D.

Pages:181–183
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.181

Preview Abstract

OBJECTIVE: This article describes pilot testing of interpersonal psychotherapy adapted for posttraumatic stress disorder (PTSD). Unlike most psychotherapies for PTSD, interpersonal psychotherapy is not exposure-based, focusing instead on interpersonal ...

January 2005

The Treatment Initiation Program: An Intervention to Improve Depression Outcomes in Older Adults

Jo Anne Sirey,Ph.D.,
Martha L. Bruce,Ph.D., M.P.H., and
George S. Alexopoulos,M.D.

Pages:184–186
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.184

Preview Abstract

OBJECTIVE: This pilot study tests the usefulness of the Treatment Initiation Program (TIP) to improve depression in older adults. The TIP is an individualized, early intervention to address older adults’ attitudes (e.g., perceived need for care and stigma)...

January 2005

A Videotape Intervention to Enhance the Informed Consent Process for Medical and Psychiatric Treatment Research

Pages:186–188
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.186

Preview Abstract

OBJECTIVE: This study evaluated a brief educational video designed to enhance the informed consent process for people with serious mental and medical illnesses who are considering participating in treatment research. METHOD: Individuals with schizophrenia ...

January 2005

Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events

Pages:189–191
Published Online:1 January 2005

https://doi.org/10.1176/appi.ajp.162.1.189

Preview Abstract

OBJECTIVE: As part of a synthesis of evidence regarding the efficacy and safety of ephedra, the authors describe data on psychiatric adverse events from reports submitted to the Food and Drug Administration (FDA). METHOD: The authors reviewed all 1,820 ...